Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide-based regimens in multiple myeloma
Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide-based regimens in multiple myeloma
复制标题
DOI：
10.3324/haematol.11319
复制
发表时间：
2007-09-01
期刊：
影响因子：
10.1
通讯作者：
Zhou, Lili
中科院分区：
文献类型：
--
作者：
Li, Yonghua;Hou, Jian;Zhou, Lili
In this study, CYP2C19 genotypes were tested by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method in 92 patients with multiple myeloma (MM). Sixty-two patients were treated with thalidomide plus dexamethasone (Thal+Dex) and 30 with thalidomide combined with chemotherapy (Thal+CC). The overall response rate of extensive metabolizers (EMS) was statistically higher than that of poor metabolizers (PMs) (62.6% vs. 33.3%, p
